HTL GROUP

high tech lab

Supplementary information and additional information to condensed quarterly financial statements for IQ2008

I. Brief description of significant achievements or failures of the issuer during the period covered by the report, including a list of the most significant events related to such achievements or failures.

1. Achieved results

Consolidated sales revenue of HTL group in 1Q2008 amounted to PLN 35,151 thousand in comparison with PLN 21,633 thousand in 4Q2007 and PLN 19,227 thousand in 1Q2007.

Consolidated net profit in 1Q2008 amounted to PLN 6,708 thousand in comparison with net loss of PLN 4,958 thousand in 4Q2007 and net profit of PLN 4,370 thousand in 1Q2007.

Sales volume of safety lancets amounted in 1Q2008 to ca. 164,700,000 pcs. (insignificantly more than disclosed in current report RB 12/2008, what results from crediting higher volume of lancets to 1Q2008 sales.)

Volume of safety lancets sales in 1Q2008 is higher by 68.2 per cent than in 4Q2007 and by 170,0 per cent than in 1Q2007.

Sales volume of personal lancets amounted in 1Q2008 to ca. 164,300,000 pcs., higher by 8,7 per cent than in 4Q2007 and lower by 6,6 per cent than in 1Q2007.

	1Q2008	4Q2007	3Q2007	2Q2007	1Q2007
Sales revenue (PLN thousand)	35,151	21,633	19,227	20,222	19,088
Net profit (PLN thousand)	6,708	(4,958)	1,249	3,554	4,370
Safety lancets sales volume (pcs.)	164,700,000	97,920,000	80,694,000	83,140,000	61,000,000
Personal lancets sales volume (pcs.)	164,300,000	151,130,000	154,900,000	140,000,000	176,000,000

1. Significant contract on personal lancets supply

HTL-STREFA S.A. on January 29th, 2008 signed a contract with Bayer HealthCare LLC Diabetes Care and Bayer Consumer Care AG concerning supply of Ascencia Microlet personal lancets.

Contract has been signed for three years. According to it HTL-STREFA S.A. is to supply Bayer with few hundred millions pieces of personal lancets a year for ca. EUR 14 million in three years. Previous supply contact was denominated in USD.

Signing contract denominated in EUR is part of HTL-STREFA S.A. plan of moving to EUR denomination, which should decrease and in the future (after Euro adoption in Poland) eliminate FX rate risk.

2. Registration of HaeMedic Polska Sp. z o.o. (a subsidiary company to HTL-STREFA S.A.)

The District Court in Warsaw on February, 18th 2008 registered HaeMedic Polska Sp. z o. o. located in Warsaw (a subsidiary company of HTL-STREFA S.A.).

A share capital of HaeMedic Polska Sp z o.o. amounts to 4,352,500.00 PLN and is divided into 87,050 shares with face value of 50.00 PLN each.

87,049 shares valued 4,352,450.00 PLN were purchased by Swedish company HaeMedic AB (a subsidiary company of HTL-STREFA S.A.). Company paid for its shares with machines and equipment used in safety lancet manufacturing.

One share with face value of 50.00 PLN was purchased by Wojciech Wyszogrodzki, CEO at HTL-STREFA S.A. and was paid in cash.

After the end of reporting period, on April 10th 2008, the Management Board of HTL-STREFA S.A. signed an agreement on purchase of 100 per cent of shares in HaeMedic Polska Sp. z o.o. HTL-STREFA S.A. purchased 87,049 shares in HaeMedic Polska Sp. z o. o. face valued PLN 4,352,450 from HaeMedic AB (subsidiary company of HTL-STREFA S.A.) and 1 share face valued PLN 50 from Wojciech Wyszogrodzki (CEO at HTL-STREFA S.A.) The price equal to face value is to be paid in cash. Current activities of HTL-STREFA S.A. were source of funds for the transaction.

I. Description of factors and events, in particular non-recurring ones, which have a significant impact on the performance;

Mentioned events did not happen in IQ2008 in HTL-STREFA S.A.

II. Discussion of seasonality (cyclical nature) of the issuer’s business in the period presented;

HTL-STREFA S.A. business does not have cyclical nature.

III. Information on any issue, repurchase or repayment of debt and equity securities;

Mentioned events did not happen in IQ2008 in HTL-STREFA S.A.

IV. Information on any dividend paid out or declared, including its total and per share value, separately for ordinary and preference shares

Management Board of HTL-STREFA S.A. recommended to shareholders to not pay out a dividend in previous years. Company's profit for the year 2007 was transferred into supplementary capital.

Management Board's priority has been assuring company's growth. Pace of the growth, especially in near years, limits, in Management Board's opinion, possibility of paying out company's profit as dividend.

Company's owners were recommended by Management Board to transfer the profit for the year 2007 on HTL-STREFA development. Annual General Meeting that held on April 24th, 2008 agreed with this proposal.

V. Events that occurred after the date of condensed quarterly financial statements, which are not included in such financial statements but may significantly affect the future performance of the issuer;

1. Purchase of HaeMedic Polska Sp. z o.o. by HTL-STREFA S.A. and launching merge procedure between HTL-STREFA S.A. and HaeMedic Polska Sp. z o.o.

On April 10th 2008, the Management Board of HTL-STREFA S.A. signed an agreement on purchase of 100 per cent of shares in HaeMedic Polska Sp. z o.o. HTL-STREFA S.A. purchased 87,049 shares in HaeMedic Polska Sp. z o. o. face valued PLN 4,352,450 from HaeMedic AB (subsidiary company of HTL-STREFA S.A.) and 1 share face valued PLN 50 from Wojciech Wyszogrodzki (CEO at HTL-STREFA S.A.) The price equal to face value is to be paid in cash. Current activities of HTL-STREFA S.A. were source of funds for the transaction.

Management Board of HTL-STREFA S.A. decided to launch a procedure to merge HTL-STREFA S.A. and HaeMedic Polska Sp. z o.o.

Merger will be conducted pursuant to article 482 §1.1 of Polish Commercial Companies Code (CCC) in accordance with art. 516 §6 CCC by acquisition of HaeMedic Polska Sp. z o.o. (acquired company) by HTL-STREFA S.A. (acquiring company), without raising of share capital in acquiring company.

Merger would allow full integration of manufacturing and sales of HaeMedic safety lancets with HTL-STREFA S.A. business. It results from acquisition od HaeMedic AB by HTL-STREFA S.A., concluded in 4Q2007.

VI. Information on any changes in contingent liabilities or contingent assets which have occurred since the end of the last financial year;

Company did not have any contingent liabilities or contingent assets at the end of 2006. This hasn't changed till the date of the statements.

Additional information

I. Description of the organizational structure of the issuer's group, specifying the undertakings subject to consolidation

HTL-STREFA S.A. group at the end of IQ2008 consisted of:
- HTL-STREFA S.A. (a parent company) located in Ozorków, Poland,
- HT Lancet Sp. z o.o. located in Łęczyca, Poland,
- HTL-STREFA Marketing Sp. z o.o. located in Warsaw, Poland,
- HTL-STREFA, Inc located in Marietta, Georgia, USA,
- HTL-STREFA GmbH located in Frankfurt am Main, Germany,
- HaeMedic AB z located in Tyresoe, Sweden.
- HaeMedic Polska Sp. z o.o. located in Warsaw.

The Group organization chart with ownership dependences at the end of I quarter of 2008 was as below:



HTL-STREFA S.A. located in Ozorków, Poland, is parent company that manufactures personal and safety lancets (also in clean-zone conditions) and moulds needles. Company's duties include also quality control of all products made by capital group and logistics.

HT Lancet Sp. z o.o. manufactures components used of safety and personal lancets. In 3Q2007 this company opened own needle grinding facility. Own needles are utilised in manufacturing personal and safety lancets.

HTL-STREFA Marketing Sp. z o.o. supports key account management, mainly on foreign markets.

HTL-STREFA, Inc supports other units in managing US key accounts and develops sales on American "alternative" market.

HTL-STREFA GmbH supports sales of group products on European market.

HaeMedic AB is the owner of trade marks and other intellectual property rights related to manufacturing of several safety lancets.

HaeMedic Polska is the owner of machines and equipment to safety lancets manufacturing and respective know-how. HaeMedic Polska Sp. z o.o. will be merged with HTL-STREFA S.A.. On April 10th, 2008 HTL-STREFA S.A. purchased 100 per cent of shares in HaeMedic Polska Sp. z o.o.

II. The effects of changes in the structure of the company, including mergers, acquisitions or disposals of the issuer's group undertakings, long-term investments, demergers, restructuring and discontinued operations;

The District Court in Warsaw on February, 18th 2008 registered HaeMedic Polska Sp. z o. o. located in Warsaw (a subsidiary company of HTL-STREFA S.A.). A share capital of HaeMedic Polska Sp z o.o. amounts to 4,352,500.00 PLN and is divided into 87,050 shares with face value of 50.00 PLN each. 87,049 shares valued 4,352,450.00 PLN were purchased by Swedish company HaeMedic AB (a subsidiary company of HTL-STREFA S.A.). Company paid for its shares with machines and equipment used in safety lancet manufacturing.

Changes in structure of the capital group were described in detail in I.3 and VI.1 of Supplementary Information.

III. The Management Board's position on the feasibility of achieving the results stated in the financial forecasts published earlier for a given year in view of the financial results presented in the quarterly report in relation to the projected results;

Due to FX risk that significantly affect Company's revenues, the Management Board decided to abandon public disclosure of forecasts denominated in PLN. The Management Board will publish annual quantitative forecasts on sales as well as forecast concerning sales revenues denominated in foreign currencies.

- **Sales volume**

Following to customers' orders and forecasts, the Management Board set sales forecast for the year 2008 (in pcs.):

	Results in IQ2008	IQ2008/Plan for FY2008	Plan for 2008Y	Results in 2007Y
Safety lancets	164,700,000	ca. 25 per cent	660,000.000	320,000,000
Personal lancets	164,300,000	ca. 18 per cent	900,000.000	620,000,000

Sales volume in IQ2008 was accordant with the planes assumed by the Management Board. Results achieved in IQ2008 could draw a conclusion that forecast will be accomplished.

- **Sales revenues**

The Management Board in 2008 forecasted to achieve following sales revenues in currencies:

Currency	Revenues in IQ2008	IQ2008 / Plan for 2008Y	Plan for 2008 Y	Results in 2007Y
EUR	ca. 4,243,000*	ca. 19 per cent	22,000,000*	7,100,000
USD	ca. 7,182,692	ca. 34 per cent	21,000,000	18,300,000
SEK	ca. 1,390,860*	---	---*	---
PLN	ca. 373,000	ca. 37 per cent	1,000,000	1,000,000

Consolidated data
* in previously disclosed forecast revenues in SEK were converted to EUR

Sales revenues in IQ2008 denominated in currencies are accordant with the plan assumed by the Management Board. Results achieved in IQ2008 could draw a conclusion that forecast will be accomplished.

IV. The shareholders holding, directly or indirectly (through subsidiary undertakings) 5% or more of the total vote at the issuer's general shareholders meeting as at date of the quarterly report, the number of shares held by such shareholders, their respective shares in the share capital, the number of votes attached to such shares and their share in the total vote at the issuer's general shareholders meeting, as well as changes in the ownership of significant blocks of the issuer shares which have occurred since the date of the previous quarterly report;

According to Board's knowledge on April, 24th 2008 list of shareholders holding at least 5 per cent of total vote at the issuer's general shareholders meeting is as below:

Shareholder	**Number of shares**	**Votes on AGM**	**Share in capital share**	**Share in total vote**
Andrzej Czernecki	25,700,000	25,700,000	40.17%	40.17%
Noryt Company Establishment	19,525,000	19,525,000	30.52%	30.52%
Wojciech Wyszogrodzki	5,000,000	5,000,000	7.81%	7.81%
Other shareholders	13,758,330	13,758,330	21.50%	21.50%
Total	**63,983,330**	**63,983,330**	**100,00%**	**100,00%**

In IQ2008 there were no changes in significant blocks of HTL-STREFA shares.

V. Statement of changes in the number of the issuer shares or rights to such shares (options) held by the issuer's managing or supervisory persons as at the date of the quarterly report, including changes in such holdings which have occurred since the date of the previous quarterly report, separately for each managing or supervisory person;

According to Board's knowledge on April, 24th 2008 list of shares held by persons from the Management Board and Supervisory Board of HTL-STREFA S.A. is as below:

Function	Name	Number of shares as on April 24th 2008	Change
The Management Board			
President of the Board	Andrzej Czernecki	25,700,000	-
Member of the Board, Ozorków Plant Director	Józef Kosowski	50,000	-
Member of the Board, CFO	Iwonna Soboń	50,000	-
Other managing persons			
Chief Executive Officer (CEO)	Wojciech Wyszogrodzki	5,000,000	-
Supervisory Board			
Chairman of Supervisory Board	Witold Orłowski	0	-
Vice-chairman of Supervisory Board	Andrzej Kidyba	0	-
Member of Supervisory Board	Beata Błędowska	0	-
Member of Supervisory Board	Jolanta Nejman	600	-
Member of Supervisory Board	Andrzej Woźnica	0	-

In HTL-STREFA S.A. the motivation scheme for management and key employees for 2007-2010 has been implemented. According to this scheme and after fulfilling its conditions (remaining Company's employee) Management Board members Iwonna Soboń and Józef Kosowski will get right to purchase not less than 100,000 and no more than 600,000 HTL-STREFA S.A. shares for face value till the end of 2010.

VI. Proceedings pending before a court, a competent arbitration body or any public administration authority including information on any proceedings concerning the issuer's or its subsidiary undertaking's liabilities or claims whose value represents 10% of the issuer's equity;

In IQ2008 there were no such proceedings concerning HTL-STREFA S.A. or its subsidiary liabilities or receivables whose value represents 10% of the issuer's equity.

VII. Information on any one or more transactions concluded by the issuer or its subsidiary undertaking with related parties which are not typical and exceed amount of EUR 500,000 unless they are typical or routine transactions concluded at arm's length by the related undertakings, whose nature and terms follow from the day-to-day operations of the issuer or its subsidiary undertaking.

HTL-STREFA S.A. and its subsidiaries did not enter in such transactions in IQ2008.

VIII. Information on sureties for loans or guarantees issued by the issuer or its subsidiary undertaking

HTL-STREFA S.A. and its subsidiaries did not conclude such activities in IQ2008.

IX. Other information which the issuer deems relevant for the assessment of its personnel, assets, financial situation, and its net result, as well as their changes, and for the assessment of the issuer's ability to perform its obligations;

In Management Board's opinion there has been no events or circumstances relevant for the assessment of HTL-STREFA S.A. personnel, assets, financial situation, and its net result, as well as their changes, and for the assessment of the HTL-STREFA S.A. ability to perform its obligations

X. Any factors which in the issuer's opinion will affect its results in a period covering at least the next quarter.

In Management Board's opinion in a period covering at least one quarter following factors will affect company's results:

1. Changes in FX rates

Revenues in EUR (after conversion to PLN) amounted to ca. 44.5 per cent of consolidated sales volume in 1Q2008, revenues in USD (after conversion to PLN) to 53.8 per cent, revenues in SEK (after conversion to PLN) to 1,5 per cent and revenues in PLN to 1,1 per cent.

Almost all sales revenue are denominated in foreign currencies, while on the other hand costs are mainly paid in PLN. Therefore sales revenue and net profit subject to significant currency risk (USD/PLN, EUR/PLN and EUR/USD). Management Board conducts activities targeting to increase share of EUR revenues (in order to decrease USD/PLN and EUR/USD risk) by signing new contracts in EUR and transforming existing contracts from USD to EUR. This is to strongly limit currency risk of HTL-STREFA S.A. after EUR adoption in Poland.

Furthermore the Management Board uses financial market instruments to hedge sales revenues against currency risk. In 1Q2008 this activities brought profits of ca. PLN 536 thousand.

2. Effects of integration of HaeMedic business with HTL group

Manufacturing processes of acquired HaeMedic business is to be moved to Poland. Efficiency of integration of acquired business with HTL group activities, as well as ability to utilise synergies (both on cost and revenue side) will be factor influencing company's performance.

3. Realisation of capacity increase plans

Constantly growing demand for HTL-STREFA products pressures to constantly increase production capacities. The characteristic of production allows to increase production capacity of specific product only by significant per cent of current capacity. Therefore Management Board keeps capacities on level only slightly higher than demanded in order to limit costs of production per one piece. Each planned increase in capacity means building new production line, which lasts 6-12 months. In case of delay of supply from external sources, it is possible that customer supply problems may occur.

In order to minimalise such risk the Management Board is ordering necessary machines and equipment as early as possible. Part of machines and equipment is produced directly by HTL-STREFA.

4. Ability to gain customers for new products

Management Board undertake activities targeting to diversification of HTLSTREFA product portfolio. It results from constantly increasing market share in presently manufactured product lines (safety and personal lancets). In 2008 HTL-STREFA share in global safety lancet market is to exceed 50%. Because of customers risk management policies it would be more difficult to increase this market share significantly.

In order to sustain pace of sales revenue growth it is planned to introduce new product lines - mainly basing on needles manufactured in own needle grinding facility. It is possible in horizon of dozen months.